Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 628

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 628
---
 Ph.D.        | ​ | ​ |  48 | ​ | ​ | Chief Executive Officer and Director                  | ​ |
| Dan Conn, J.D., M.B.A.      | ​ | ​ |  57 | ​ | ​ | Chief Financial Officer                               | ​ |
| John Kauh, M.D.             | ​ | ​ |  51 | ​ | ​ | Chief Medical Officer                                 | ​ |
| Jeffrey Larson, Ph.D., DABT | ​ | ​ |  63 | ​ | ​ | Senior Vice President, Research & Development         | ​ |
| Yixin “Joseph” Chen, Ph.D.  | ​ | ​ |  64 | ​ | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ |
| Sujal Shah                  | ​ | ​ |  51 | ​ | ​ | Chairman of the Board                                 | ​ |
| Wallace Hall                | ​ | ​ |  62 | ​ | ​ | Director                                              | ​ |
| Shaheen Wirk, M.D.          | ​ | ​ |  47 | ​ | ​ | Director                                              | ​ |
| Michael Wygza               | ​ | ​ |  69 | ​ | ​ | Director                                              | ​ |

Executive Officers Imran Alibhai, Ph.D. has served as Tvardi’s Chief Executive Officer and a member of its board of directors since December 2018. Since 2018, Dr. Alibhai has also served on the Scientific Advisory Board for NASA’s Translational Research Institute for Space Health. Prior to serving as Tvardi’s Chief Executive Officer, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotechnology company developing oncolytic viruses for cancer from 2014 to 2018. From 2010 to 2013, Dr. Alibhai was an investment banker in Peter J. Solomon’s Healthcare Advisory Group, focused on M&A transactions in science-based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. From 2007 to 2010, Dr. Alibhai served as the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. From 2006 to 2007, he directed investments for PIPE’s and long/short positions in MPM Capital’s BioEquities hedge fund. Dr. Alibhai received a Ph.D. in